Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.
Novartis
Novartis
Washington University School of Medicine
University Hospital, Limoges
Eli Lilly and Company
Pfizer
Kelonia Therapeutics, Inc.
Quetzal Therapeutics
Medical College of Wisconsin
Orca Biosystems, Inc.
Taiho Oncology, Inc.
Celgene
Cellectar Biosciences, Inc.
Center for International Blood and Marrow Transplant Research
Takeda
Thomas Jefferson University
Medical College of Wisconsin
Cogent Biosciences, Inc.
Eli Lilly and Company
Massachusetts General Hospital
H. Lee Moffitt Cancer Center and Research Institute
Kedrion S.p.A.
Ossium Health, Inc.
Memorial Sloan Kettering Cancer Center
Center for International Blood and Marrow Transplant Research
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Eli Lilly and Company
Medical College of Wisconsin
University of Michigan Rogel Cancer Center
Nantes University Hospital
Brigham and Women's Hospital
Herlev and Gentofte Hospital
Eli Lilly and Company
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Stanford University
Pfizer
Fred Hutchinson Cancer Center
The First Affiliated Hospital of Guangzhou Medical University
Zhejiang University
University of Colorado, Denver
Massachusetts General Hospital
Constellation Pharmaceuticals
Centre Hospitalier Universitaire de la Réunion
Takeda
Dana-Farber Cancer Institute
Zhejiang University
Azienda USL Reggio Emilia - IRCCS
Fred Hutchinson Cancer Center
Cogent Biosciences, Inc.
Eli Lilly and Company